Large Language Models such as GPT-4o and GPT-5 achieve strong zero-shot performance on biomedical claim verification, but cost and opacity limit scalable use. We fine-tune three small LLMs: Phi-3-mini (3.8B), Qwen2.5-3B, and Mistral-7B, via QLoRA on SciFact and HealthVer, providing the first study of QLoRA models against GPT-4o and fine-tuned BioLinkBERT encoders. Mistral-7B QLoRA surpasses both GPT-4o and GPT-5 (up to 12% F1 gain) at a fractional cost using just 1,008 training examples. We conduct extensive in-domain and cross-domain evaluation: models trained on SciFact tested on HealthVer and vice versa, at matched sizes to isolate dataset structure from data quantity. We identify a previously unreported structural artifact in SciFact that inflates in-domain scores, and show through bidirectional out-of-domain evaluation that training on structurally sound data enables robust cross-domain transfer. We plan to release all code and adapter checkpoints.
Medical RAG systems in high-risk QA settings are often evaluated through a single answer-or-abstain decision, but mixed evidence may support one claim, require conditions for another, and contradict a third. We study claim-selective certification: each response is decomposed into verifiable claims, scored against retrieved evidence, and mapped by an intent-aware selector to {full, partial, conflict, abstain}. On the primary weak-label certificate protocol, whose real-source-only dev/test rows cover the naturally occurring non-abstain actions, the full system records UCCR=0.0000, PAU=1.0000, PAU Precision=0.9901, and action accuracy=0.9204 on dev (n=314), and UCCR=0.0000, PAU=0.9967, PAU Precision=0.9739, and action accuracy=0.8997 on test (n=319). UCCR measures unsupported-claim risk within the certificate definition, and a source-missing counterfactual slice evaluates abstain under empty evidence. Shortcut controls quantify the action-label prior explained by source and intent metadata, while source/evidence-novel slices characterize transfer boundaries. The resulting interface separates action-label prediction from evidence-linked claim selection under mixed evidence.